Mucopolysaccharidosis VI (MPS VI) (マロト‐ラミー症候群):グローバル臨床試験動向(2014年上半期)

◆英語タイトル:Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome) Global Clinical Trials Review, H1, 2014
◆発行会社/調査会社:GlobalData
◆商品コード:GDHC2167CTIDB
◆発行日:2014年5月26日
◆調査対象地域:グローバル
◆ページ数:71
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥277,500見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD5,000 ⇒換算¥555,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD7,500 ⇒換算¥832,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の市場調査資料のご購入、委託調査サービスに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[Mucopolysaccharidosis VI (MPS VI) (マロト‐ラミー症候群):グローバル臨床試験動向(2014年上半期)]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome) Global Clinical Trials Review, H1, 2014

Summary

GlobalData’s clinical trial report, “Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome) Global Clinical Trials Review, H1, 2014″ provides data on the Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

*** レポート目次(コンテンツ)***

Table of Contents
Table of Contents2
List of Tables 4
List of Figures 5
Introduction 7
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) 7
Report Guidance 7
Clinical Trials by Region 8
Clinical Trials and Average Enrollment by Country 9
Top Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Top Countries Contributing to Clinical Trials in Middle East and Africa 14
Top Countries Contributing to Clinical Trials in Central and South America 15
Clinical Trials by G7 Countries: Proportion of Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) to Metabolic Disorders Clinical Trials 16
Clinical Trials by Phase in G7 Countries 17
Clinical Trials in G7 Countries by Trial Status 18
Clinical Trials by E7 Countries: Proportion of Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) to Metabolic Disorders Clinical Trials 19
Clinical Trials by Phase in E7 Countries 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) 25
Subjects Recruited Over a Period of Time 27
Clinical Trials by Sponsor Type 28
Prominent Sponsors 29
Top Companies Participating in Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials 30
Prominent Drugs 31
Clinical Trial Profiles 32
Clinical Trial Overview of Top Companies 32
BioMarin Pharmaceutical Inc. 32
Clinical Trial Overview of BioMarin Pharmaceutical Inc. 32
Sanofi 33
Clinical Trial Overview of Sanofi 33
ReGenX Biosciences, LLC 34
Clinical Trial Overview of ReGenX Biosciences, LLC 34
Medical Resources International Pte Ltd 35
Clinical Trial Overview of Medical Resources International Pte Ltd 35
Cytomedix, Inc. 36
Clinical Trial Overview of Cytomedix, Inc. 36
Clinical Trial Overview of Top Institutes / Government 37
University of Minnesota 37
Clinical Trial Overview of University of Minnesota 37
Masonic Cancer Center 38
Clinical Trial Overview of Masonic Cancer Center 38
Greenwood Genetic Center 39
Clinical Trial Overview of Greenwood Genetic Center 39
The University of Chicago 40
Clinical Trial Overview of The University of Chicago 40
University of Rostock 41
Clinical Trial Overview of University of Rostock 41
Clinical and Translational Science Institute 42
Clinical Trial Overview of Clinical and Translational Science Institute 42
Fairview University Medical Center 43
Clinical Trial Overview of Fairview University Medical Center 43
New York Medical College 44
Clinical Trial Overview of New York Medical College 44
Tehran University of Medical Sciences 45
Clinical Trial Overview of Tehran University of Medical Sciences 45
Five Key Clinical Profiles 46
Appendix 69
Abbreviations 69
Definitions 69
Research Methodology 70
Secondary Research 70
About GlobalData 71
Contact Us 71
Disclaimer 71
Source 71

List of Tables
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics, Global, Clinical Trials by Region, 2014* 8
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 9
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 10
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2014* 11
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials, Europe, Top Countries, 2014* 12
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials, North America, Top Countries, 2014* 13
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 14
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 15
Proportion of Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) to Metabolic Disorders Clinical Trials, G7 Countries (%), 2014* 16
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 17
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 18
Proportion of Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) to Metabolic Disorders Clinical Trials, E7 Countries (%), 2014* 19
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 20
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics, Global, Suspended Clinical Trials, 2014* 25
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics, Global, Terminated Clinical Trials, 2014* 26
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 27
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 28
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 29
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 30
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 31
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials Market, Global, Clinical Trials by BioMarin Pharmaceutical Inc., 2014* 32
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi, 2014* 33
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials Market, Global, Clinical Trials by ReGenX Biosciences, LLC, 2014* 34
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials Market, Global, Clinical Trials by Medical Resources International Pte Ltd, 2014* 35
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials Market, Global, Clinical Trials by Cytomedix, Inc., 2014* 36
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Minnesota, 2014* 37
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials Market, Global, Clinical Trials by Masonic Cancer Center, 2014* 38
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials Market, Global, Clinical Trials by Greenwood Genetic Center, 2014* 39
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Chicago, 2014* 40
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Rostock, 2014* 41
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials Market, Global, Clinical Trials by Clinical and Translational Science Institute, 2014* 42
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials Market, Global, Clinical Trials by Fairview University Medical Center, 2014* 43
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials Market, Global, Clinical Trials by New York Medical College, 2014* 44
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials Market, Global, Clinical Trials by Tehran University of Medical Sciences, 2014* 45

List of Figures
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics, Global, Clinical Trials by Region (%), 2014* 8
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 9
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 10
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials, Europe, Top Countries (%), 2014* 12
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 13
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2014* 14
Proportion of Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) to Metabolic Disorders Clinical Trials, G7 Countries (%), 2014* 16
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 17
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 18
Proportion of Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) to Metabolic Disorders Clinical Trials, E7 Countries (%), 2014* 19
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 20
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 27
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 28
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 29
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 30
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 31
GlobalData Methodology 70

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(GDHC2167CTIDB )"Mucopolysaccharidosis VI (MPS VI) (マロト‐ラミー症候群):グローバル臨床試験動向(2014年上半期)" (英文:Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome) Global Clinical Trials Review, H1, 2014)はGlobalData社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。